InterCure Ltd. (NASDAQ:INCR – Get Rating) saw a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 79,600 shares, a drop of 6.9% from the July 15th total of 85,500 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 55,400 shares, the days-to-cover ratio is currently 1.4 days.
InterCure Stock Down 3.2 %
INCR stock opened at $6.02 on Wednesday. The firm has a market cap of $257.26 million and a PE ratio of 50.17. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.26 and a current ratio of 1.67. The firm's fifty day moving average is $6.00 and its 200 day moving average is $6.37. InterCure has a one year low of $5.42 and a one year high of $8.77.
Get
InterCure alerts:
InterCure (NASDAQ:INCR – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported $0.11 EPS for the quarter. The company had revenue of $27.29 million for the quarter. InterCure had a net margin of 5.38% and a return on equity of 3.23%.
Institutional Trading of InterCure
Institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC lifted its stake in shares of InterCure by 70.4% in the second quarter. Citadel Advisors LLC now owns 25,661 shares of the company's stock worth $149,000 after buying an additional 10,598 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of InterCure by 756.0% in the second quarter. JPMorgan Chase & Co. now owns 6,309 shares of the company's stock worth $37,000 after buying an additional 5,572 shares in the last quarter. Citigroup Inc. lifted its stake in shares of InterCure by 9,567.9% in the first quarter. Citigroup Inc. now owns 5,124 shares of the company's stock worth $36,000 after buying an additional 5,071 shares in the last quarter. Davy Global Fund Management Ltd purchased a new position in shares of InterCure in the first quarter worth about $152,000. Finally, ETF Managers Group LLC purchased a new position in InterCure during the fourth quarter worth about $3,592,000. Institutional investors and hedge funds own 9.34% of the company's stock.
About InterCure
(Get Rating)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector.
See Also
- Get a free copy of the StockNews.com research report on InterCure (INCR)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Why Apple is Primed to Take a Bite Out of Live Sports
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
